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Abstract
Neurofibromatosis 2 (NF2) is an autosomal dominant disease in which hearing loss is predominant. 
Auditory restoration is possible using cochlear implants (CI) or auditory brainstem implant (ABI).
Objective: To assess the auditory results of CI and ABI in NF2 patients and review the literature.
Methods: Four NF2 patients were prospectively evaluated. They were submitted to tumor resection 
followed by ipsilateral CI or ABI depending on cochlear nerve preservation. Long term auditory 
results were described for CI (12 months) and ABI (48 months).
Results: All patients achieved auditory perception improvements in their hearing thresholds. The 
CI patient does not recognize vowels or sentences. The 3 ABI patients discriminate 70% of vowels 
and 86% in the 4-choice test. One of them does not recognize sentences. The other two recognize 
100% of closed sentences and 10% and 20% of open sentences.
Conclusion: The choice of implant type to restore hearing to NF2 patients will relay on anatomical 
and functional cochlear nerve preservation during tumor resection surgery. Although our experience 
was different, the literature shows that if this condition is achieved, CI will offer better auditory 
results. If not, ABI is recommended.
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INTRODUCTION
Neurofibromatosis type 2 (NF2) is a dominant 
autosomal disease which affects 1:40,000 individu-
als1,2. In these cases there is a two allele mutation 
on the chromosome 22 long arm tumor suppres-
sor gene1,2. The patients usually develop multiple 
schwannomas along the spine and in the skull. 
Bilateral vestibular schwannoma happens in 90% of 
those with the gene1. These patients will invariably 
develop progressive sensorineural hearing loss, 
characterized by poor sound discrimination. Tinnitus 
and unbalance may also happen1.
The auditory rehabilitation of patients who 
evolved to a severe-profound hearing loss, until very 
recently was restricted to them learning lip reading. 
In 1979, House and Hitselberger started to change 
this story when they performed the first single chan-
nel auditory brainstem implant (ABI) in a NF2 deaf 
patient3. The implant electrode bundle has improved 
with the years, going from 8 to 21 electrodes4. This 
technological progress has benefited over 700 pa-
tients implanted with the ABI, with variable auditory 
responses1,2,4-8.
During the 90’s, the cochlear implant (CI) 
also became available for the rehabilitation of deaf 
patients with NF2 submitted to tumor resection with 
cochlear nerve preservation9-15.
The auditory rehabilitation of NF2 patients may 
be carried out in two different ways (CI or ABI). We 
will, hereby, report on the auditory results from four 
patients with NF2 submitted to brainstem or cochlear 
auditory implant surgery in our clinic, and review 
the literature on this topic.
METHOD
We prospectively assessed four NF2 patients 
submitted to vestibular schwannoma exeresis surgery 
during February of 2006 and March of 2009. The 
ipsilateral brainstem implant (ABI) or the cochlear 
implant (IC) was carried out in the same procedure, 
depending on cochlear nerve preservation.
Clinical and radiological data were collected 
before surgery, stressing auditory performance, au-
ditory deprivation time and tumor size.
Three patients were implanted through the 
translabyrinthine approach with the Nucleus 24® 
ABI (Cochlear Corporation) after tumor removal. In 
order to assess the lateral wall of the IV ventricle 
(Luschka’s foramen). As anatomical landmarks, we 
used the following: the IX cranial nerve, the acoustic-
-facial trunk, the cerebellar flocculus and the choroid 
plexus. During the surgeries, the VII, IX, X and XI 
ipsilateral cranial nerves were continuously monito-
red (NIM Response-2; Medtronic Xomed).
Brainstem electrically evoked auditory poten-
tials (electrical ABR) were used to check for proper 
positioning of the electrode bundle, by means of the 
Biologic Navigator Pro (Bio-logic Systems Corp.®) 
device, coupled to the implant stimulation interface 
through a sync cable.
In one patient, the cochlear nerve anatomical 
preservation was possible during tumor exeresis 
through the retrolabyrinthine approach. The pro-
montory electrical stimulation test during surgery 
showed a present response, although with poor 
morphology and dubious reproducibility. We de-
cided to use the Nucleus Freedom Contour Advan-
ced® (Cochlear Corporation) simultaneous cochlear 
implant through the round window. In such case, 
intraoperative neural telemetry showed no response 
in the five electrodes tested. The electrode bundle 
positioning was checked after surgery through Sten-
vers and transorbital view x-rays.
Checking electrode impedances, both in ABI 
as well as in CI showed inadequate values.
ABI activation was done approximately 1 
month after the surgery, with the patient awake in 
an ICU unit with cardiorespiratory monitoring. The 
electrodes were sequentially activated with a mono-
polar current, with a gradual increase for recording a 
comfortable auditory sensation and side effects. The 
speech coding strategy used in the three patients was 
the Spectral peak (Speak). CI activation was carried 
out after surgery and the speech coding strategy was 
the advanced combination encoders (ACE).
The auditory results after 48 months using the 
ABI and 12 months using the CI were expressed in: 
tonal thresholds in a sound field, four-choice test, 
vowel and phrases recognition index presented in 
a closed and open format, telephone use.
For the literature review, we used the following 
keywords: (cochlea or cochlear or auditory or ear) 
and (brain implant or brain implants), in the Me-
dline, Lilacs and Scielo databases, with the limit of 
publication period up to March of 2010. We found 
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Table 1. Classification of the papers used in the Literature Review.
Authors Year Sample Type of Study Intervention Strength of Evidence
Recommendation 
Grade
Tono et al. (1996) 1 Case Report CI 4 C
Grahan et al. (1999) 1 Case Report CI 4 C
Erbinger et al. (2000) 88 Clinical Trial ABI 2b B
Nevinson et al. (2002) 27 Treatment Results Observation ABI 2c B
Nolle et al. (2003) 1 Case Report CI 4 C
Otto et al. (2004) 20 Treatment Results Observation ABI 2c B
Kanowitz et al. (2004) 18 Treatment Results Observation ABI 2c B
Colletti & Shannon (2005) 20 Treatment Results Observation ABI 2c B
Aristegui & Denia (2006) 1 Case Report CI 4 C
Lustig et al. (2006) 7 Treatment Results Observation CI 2c B
Behr et al. (2007) 20 Treatment Results Observation ABI 2c B
Bento et al. (2008) 4 Case Series prospective ABI 4 C
Grayeli et al. (2008) 31 Case Series retrospective ABI 4 C
Otto et al. (2008) 10 Treatment Results Observation CI 2c B
Vincenti et al. (2008) 5 Cohort Study prospective ABI/CI 2b B
Maini et al. (2009) 10 Case Series retrospective ABI 4 C
Temple et al. (2009) 1 Case Report CI 4 C
ABI: Auditory Brain Stem Implant; CI: Cochlear Implant.
Table 2. Clinical and epidemiological data of the NF2 patients implanted with ABI and CI.
Deafness tumor Age (years) Gender Duration (years) Side Size (cm) Approach Implant type
Case 1 28 M 10 L 3.5 TL N24 ABI
Case 2 25 M 6 L 4.0 TL N24 ABI
Case 3 26 M 2 L 2.0 TL N24 ABI
Case 4 36 F 1 R 1.5 RL CI N24 RE
TL: Translabyrinthine approach; RL: Retrolabyrinthine; N24 ABI: Auditory Brainstem Implant Nucleus 24; IC 24 RE: Cochlear Implant Freedom 
Contour; L: Left; R: Right.
1118 publications. Of these, there were 17 clinical 
trials with NF2 patients submitted to cochlear or 
brainstem auditory implant, in English or Portuguese. 
Each study was classified according to its strength 
of evidence, according to the classification from 
the Oxford Centre for Evidence-based Medicine 
for studies on treatment (Table 1). Later on, these 
studies were also classified according to the degree 
of recommendation, nine publications with recom-
mendation grade B and eight with recommendation 
grade C (Table 1).
This study was approved by the Ethics Com-
mittee for Research Project Analysis of our institution, 
under protocol number 1135/07. Extensive explana-
tion on the risks and benefits of brainstem auditory 
implant surgery and the option to continue only with 
the lip reading training therapy were given to the 
patients. Signing the Informed Consent Form meant 
agreeing to participate in the study.
RESULTS
The three patients implanted with an ABI were 
males, with a mean age of 26.3 ± 1.5 years, mean 
deafness duration of 6.0 ± 4.0 years and mean tumor 
size of 3.2 ± 1.4 cm (Table 2). They all regularly used 
their devices for more than eight hours a day. None 
of them used a personal sound amplification device 
(PSAD) in the contralateral ear.
No additional postoperative complication was 
observed on these patients by placing the ABI. Two 
patients had post-operative facial paralysis, keeping 
a House-Brackmann score of VI. One developed a 
CSF fistula, treated by an external lumbar shunt and 
compressive brain dressing. The adverse effects seen 
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The patient implanted with CI was 36 years 
old, with a 10-year history of progressive hearing 
loss, evolving towards a severe hearing loss for 1 year 
(Table 2). The tumor on the implanted side measured 
1.5 cm (Table 2). She also used her implant regularly 
for more than 8 hours a day and used a contralateral 
PSAD for 7 months, with low sounds perception.
Upon activation, there were five electrodes 
with auditory sensation and without side effects. 
After 12 months of stimulation, 11 electrodes could 
be activated without side effects. The audiometric 
threshold in a free field improved after the CI, the 
mean values for the following frequencies: 500; 
1,000; 2,000 and 4,000 Hz was 46.2 decibels (Graph 
1). Despite the improvement in tonal thresholds, 
the patient managed to detect only the presence of 
sound, not discriminating phrases, words, vowels, 
and rhythm (Table 4).
SYSTEMATIC REVIEW OF THE LITERATURE 
AND DISCUSSION
The auditory rehabilitation of NF2 patients, 
who develop deafness, may be carried out in two 
ways: auditory cochlear or brainstem implants2,3. The 
choice of implant type to the utilized will depend 
on the anatomical and functional preservation of the 
cochlear nerve during the tumor resection surgery2,3. 
In these regards, electrophysiological tests have a 
crucial role in the identification of cochlear nerve 
responses.
This can be done during the procedure, stu-
dying the cochlear nerve action potential2. If this po-
tential is present, the cochlear implant can be placed 
simultaneously with the tumor resection. Should this 
potential be absent or not reproducible, one should 
perform the promontory electrical stimulation test 6 
to 8 weeks after the procedure2. In the immediate 
post-op, the electrical stimulation test on the pro-
montory may be negative because of cochlear nerve 
neuropraxia, caused by surgical manipulation2. Such 
test is based on the introduction of a transtympanic 
Table 3. Number of active electrodes in patients implanted with 
the ABI and the CI.
# of active electrodes 3 m 12 m 36 m 48 m
Case 1 2 2 3 3
Case 2 6 5 4 4
Case 3 14 14 14 14
Case 4 5 11 x x
x: does not apply by the duration of cochlear implant use.
Table 4. Auditory results in patients implanted with the ABI and CI at 3, 12, 36 and 48 months after surgery.
Vowels (%) Four Choice (%) Closed Phrases (%) Open phrases (%)
3 m 12 m 36 m 48 m 3 m 12 m 36 m 48 m 3 m 12 m 36 m 48 m 3 m 12 m 36 m 48 m
Case NR NR 100 100 NR 100 100 100 NR NR 100 100 NR NR 20 20
Case 2 73 26 40 30 91 41 50 58 30 0 0 0 0 0 0 0
Case 3 66 NR 20 80 100 100 100 100 100 100 100 100 0 0 60 60
Case 4 0 0 x x 0 0 x x 0 0 x x 0 0 x x
NR: not done; x: does not apply by the duration of cochlear implant use.
Graph 1. Free field audiometric thresholds before and after the implant.
during the ABI activation were: throat stimulation (1), 
torso (2), upper (2) and lower limbs (1), nausea (1) 
and nystagmus (1). The number of electrodes whi-
ch generate hearing sensation without side effects 
varied between 2 and 14 (Table 3).
The mean value of the audiometric threshold 
in the free field using the device with ABI patients 
in the frequencies of 500; 1,000; 2,000 and 4,000 
Hz was 36.7 ± 5.7 decibels (Graph 1). The tonal 
thresholds reached were similar among the patients 
and were maintained stable throughout the years. 
Auditory performance varied, one patient does not 
recognize open sentences and only 20% closed ones. 
The other two recognize 100% of the phrases and 
10% and 20% open (Table 4). Only one of them was 
capable of communicating on the phone.
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Table 5. Auditory results in patients implanted with the CI described in the literature.
Case Age (years)
Deafness duration 
(months)
Follow up time 
(months)
Open phrases 
(%) Electrophysiological test
Vincenti et al. (2008)2 47 3 12 90 Good promontory stimulus
Vincenti et al. (2008)2 24 0 12 81 Good cochlear nerve action potential
Vincenti et al. (2008)2 32 3 12 50 Good promontory stimulus
Vincenti et al. (2008)2 36 3 12 0 Doubtful cochlear nerve potential and promontory stimulus
Tono et al. (1996)11 31 15 12 62 Good promontory stimulus
Temple et al. (1999)17 15 9 12 100 Good promontory stimulus
Nölle et al. (2003)14 16 24 24 88 Good promontory stimulus
Grahan et al. (1999)12 44 84 6 34 Promontory stimulus present
Aristegui & Denia (2005)15 52 ND 18 100 NCO (Obs. Viable contralateral hearing)
Lustig et al. (2006)16 35 5 28 0 NCO (Obs. Viable contralateral hearing)
Lustig et al. (2006)16 51 5 40 0 NCO (Obs. Viable contralateral hearing)
Lustig et al. (2006)16 16 13 30 0 NCO
Lustig et al. (2006)16 41 36 17 0 NCO
Lustig et al. (2006)16 28 4 88 0 NCO
Lustig et al. (2006)16 50 22 18 98 NCO
Lustig et al. (2006)16 57 96 9 21 NCO
ND: Not Described; NCO: Not Carried Out.
needle, under local anesthesia, which will contact 
the promontory. The electrical stimulus is provided 
to the promontory in five different frequencies (50, 
100, 200, 400 and 800 Hz) and the current level, 
initially of 0 µAmps, is progressively increased until 
the patient hears of perceives the stimulus2. The test 
is deemed positive when there is mild perception 
of a tone and differentiation between the different 
pitches. The test is deemed negative when the pa-
tient feels only a discomfort caused by the electrical 
stimulus2.
The literature has data on eight patients with 
anatomical preservation of the cochlear nerve, sub-
mitted to CI surgery, but without functional proof 
by an electrophysiological test, with results which 
were lower than those from a group of patients with 
cochlear nerve functional confirmation15,16 (Table 5). 
Only three of the eight cases had phrases discrimi-
nation15,16 (Table 5). The data from the other group 
with six patients with anatomical and functional 
preservation of the cochlear nerve, proven by elec-
trophysiological tests, showed phrase discrimination 
in all the cases, with a mean value of 74.5 ± 18.8% 
(50-100)2,16,17 (Table 5).
However, in one case of promontory stimula-
tion, with a long time between the tumor resection 
surgery and the cochlear implant, the discrimination 
of open phrases was worse12 (Table 5). In this case, 
the cochlear basal turn was found to be ossified 
during surgery, suggesting that the insertion of the 
electrode bundle in the cochlea, when not together 
with the tumor removal, must be carried out in the 
shortest possible time in order to avoid cochlear 
ossification consequent to surgical manipulation12. 
In one case with cochlear nerve anatomical pre-
servation, but with questionable response upon 
the promontory electrical stimulation test as to the 
nerve’s action potential, speech discrimination was 
not achieved2 (Table 5). We found the same thing 
in our CI patient; despite cochlear nerve anatomical 
preservation, the promontory electrical stimulation 
test yielded poor responses and the patient did not 
discriminate the sounds; thus, the importance of 
functional proof of the nerve in order to obtain a 
good audiological result.
When it was not possible to spare the cochlear 
nerve during the vestibular schwannoma resection 
surgery or when its anatomical sparing did not 
generate electrophysiological responses, the only 
feasible option for the auditory rehabilitation is the 
brainstem auditory implant1,2,4-6,16,18-21.
Studies have shown that the ABI (Auditory 
Brainstem Implant) has variable audiological res-
ponses. Nonetheless, it is a consensus that the ABI 
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enables the perception of alert environmental sounds 
between 85%7 to 96.2%5 of the patients after one 
year of surgery, besides enhancing lip reading5,18,20.
Patients with auditory perception recognize 
the difference between the human speech sound 
and environmental sound and 64% recognize the 
difference between the voices from female/male 
and adult/children5. The mean open phrase recog-
nition after one year using the ABI varies among the 
studies from 5% to 48%, together with lip reading, 
the values vary between 25 and 79%20. In general, 
the ABI provides an additional gain between 30% 
and 40% compared to lip reading only1,2,5,18-20. Using 
a telephone is not an expected result, being the 
exception to the rule2,5.
The benefit provided by the ABI does not 
discard training in lip reading and multidiscipli-
nary rehabilitation is very important for patient 
improvement1. Even after one year using the ABI, 
improvements continue to be seen4. In our series, 
one of the patients had a worsening in his auditory 
perception along the years, despite the fact that his 
tonal thresholds had improved. Of the six working 
electrodes he had, only four remained. We do not 
know, for sure how to explain such worsening, but 
since this is the patient with the largest tumor, we 
speculate that there could have been a progressive 
damage to the cochlear core, corroborated by the 
progressive electrode deactivation time. The electro-
des are deactivated when the stimuli do not generate 
significant auditory input or causes extra-auditory 
inputs (side effects by stimulation from adjacent co-
res). In this patient, as time passed, it was necessary 
to increase the electrical charge in order to generate 
an auditory input, which caused greater stimulation 
scatter and more pronounced side effects.
Comparing the literature results obtained 
from NF2 patients with cochlear nerve function 
and anatomical preservation, submitted to CI with 
those submitted to ABI, there were no great diffe-
rences in relation to the recognition of vowels and 
consonants2. The recognition of dissyllable words 
and phrases was higher with the cochlear implant2. 
Moreover, most of the patients implanted with a CI 
are able to use the telephone.
CONCLUSION
Patients with neurofibromatosis type 2 have 
now the technological resources which help in the 
auditory rehabilitation, providing an additional gain 
upon lip reading training. Although our experience 
has shown the opposite, literature shows that when 
possible to anatomically and functionally spare the 
cochlear nerve, the cochlear implant yields better 
auditory and language results. When cochlear nerve 
sparing is not possible, the brainstem auditory im-
plant may be used for the same end.
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